In early clinical trials, midostaurin showed limited and transient activity as a single-agent treatment and induced about a 50% reduction in peripheral and bone marrow blast counts in relapsed/refractory (R/R) AML patients with FLT3 mutation [38]. This evidence concerns the gene FLT3 and acute myeloid leukemia.